



Scholar Rock to Present at Upcoming Investor Conferences

August 27, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 27, 2026-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that management will participate in the following investor conferences:

- **Cantor 2026 Global Healthcare Conference:** Scholar Rock is scheduled to participate in a fireside chat at 8:00 a.m. ET on Wednesday, September 9, 2026 in New York, NY.
- **Citi 2026 BioPharma Back to School Conference:** Scholar Rock is scheduled to participate in a fireside chat at 9:20 a.m. ET on Thursday, September 10, 2026 in New York, NY.

A live webcast of the events will be available under the “Events and Presentations” page within the Investors section of the Scholar Rock website at <http://investors.scholarrock.com>. A replay of the webcasts will be available for approximately 90 days.

About Scholar Rock

Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors and the public using our company website, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website, X, or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260827770946/en/>

Investors

Laura Ekas, Ph.D.
917-439-0374
ir@scholarrock.com

Media

Jeff Smith
682-401-8428
Molly MacLeod, Ph.D.
802-579-5995
media@scholarrock.com

Source: Scholar Rock